Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Malignant Pleural Mesothelioma
NCT03048474Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in malignant pleural mesothelioma (MPM), sponsored by Netherlands Cancer Institute. Started Sep 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03048474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048474.